mouse anti crmp2 monoclonal (Bioss)
Structured Review

Mouse Anti Crmp2 Monoclonal, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti crmp2 monoclonal/product/Bioss
Average 90 stars, based on 2 article reviews
Images
1) Product Images from "Probenecid Disrupts a Novel Pannexin 1-Collapsin Response Mediator Protein 2 Interaction and Increases Microtubule Stability"
Article Title: Probenecid Disrupts a Novel Pannexin 1-Collapsin Response Mediator Protein 2 Interaction and Increases Microtubule Stability
Journal: Frontiers in Cellular Neuroscience
doi: 10.3389/fncel.2018.00124
Figure Legend Snippet: Pannexin 1 (Panx1) and collapsin response mediator protein 2 (Crmp2) interact. (A) Crmp2 peptides (red) identified previously by immunoprecipitation (IP) coupled to LC-MS/MS in Wicki-Stordeur and Swayne . Peptides were identified specifically in IPs from Panx1-EGFP expressing Neuro-2a (N2a) cells, and not EGFP controls. (B) Western blot of endogenous IPs from N2a cell lysates. (i) Crmp2 precipitates specifically with Panx1 compared with IgG control. (ii) Panx1 precipitates specifically with Crmp2 compared with IgG control. (C) Western blots of an in vitro binding assay using purified Crmp2 and Panx1 C-terminus (Panx1CT). (i) The Panx1CT enriches with immobilized Crmp2-GST compared with GST control. (ii) Crmp2 enriches with Panx1CT-GST compared with GST control. These results are representative of three independent replicates. For the complete blots of parts (B,C) , see Supplementary Material. This data was previously included in the PhD thesis of LWS (link: https://dspace.library.uvic.ca/handle/1828/6938 ).
Techniques Used: Immunoprecipitation, Liquid Chromatography with Mass Spectroscopy, Expressing, Western Blot, In Vitro, Binding Assay, Purification
Figure Legend Snippet: Validation of the Panx1-Crmp2 interaction in the mouse ventricular zone (VZ). (Ai) Western blot of a time course of Panx1 and Crmp2 expression in the VZ. (ii) Panx1 expression peaked within the early postnatal period (P0–P7), and dramatically decreased with age (P28–P60; p = 0.0365 by one-way analyses of variance (ANOVA); F (4,10) = 3.9; Dunnett’s multiple comparison test post hoc , P28 p = 0.0352, and P60, p = 0.0177; n = 3). Coomassie Blue was employed as a loading control. (iii) Crmp2 expression remained relatively constant across this time course ( F (4,10) = 1.3; p = 0.3333, one-way ANOVA; n = 3). (B) Western blot of endogenous Panx1 IPs from mouse brain VZ tissue. Crmp2 co-precipitated specifically with Panx1 from young (P10; i ) and adult (P60; ii ) mouse VZ. For the complete blots of part (B) , see Supplementary Material. This data was previously included in the PhD thesis of LWS (link: https://dspace.library.uvic.ca/handle/1828/6938 ).
Techniques Used: Western Blot, Expressing
Figure Legend Snippet: Probenecid treatment decreases Crmp2 co-precipitation with Panx1. (Ai) Western blot of a GFP IP from N2a cells expressing Panx1-EGFP, or EGFP control, treated (16 h) with probenecid or vehicle control. (ii) Probenecid treatment (16 h) significantly decreased the amount of Crmp2 that precipitated with Panx1-EGFP. Crmp2 signal in the IP fraction was normalized to GFP signal intensity from the same lane (Panx1-EGFP [vehicle] vs. Panx1-EGFP [probenecid]: 100.0 ± 0.8 vs. 39.4 ± 19.6, p = 0.0368, n = 3, unpaired t -test). (B) The same assay was performed with a shorter 30 min treatment (i) . (ii) Short probenecid treatment (30 min) revealed a ~30% decrease in Crmp2 co-precipitation (Panx1-EGFP [vehicle] vs. Panx1-EGFP [probenecid]: 100.0 ± 11.1 vs. 67.7 ± 19.6, p = 0.0826, n = 3, unpaired t -test). (C) PNGase F treatment was performed to confirm the upper Panx1EGFP immunoreactive band was indeed glycosylated Panx1 and assessed by Western blotting. Note that both immunoreactive bands shifted in response to N-glycosidase F treatment, suggesting that both major bands are mature glycosylated Panx1EGFP of differing molecular weights. (D) Analysis of the input intensities revealed that probenecid treatment did not change the overall expression of (i) Crmp2 ( p = 0.2000, Mann-Whitney test, n = 3) or (ii) Panx1 ( p = 0.578, unpaired t -test, n = 3). Normalized to Gapdh (not shown), n.s., non-significant.
Techniques Used: Western Blot, Expressing, MANN-WHITNEY
Figure Legend Snippet: Probenecid decreases proximity ligation assay (PLA) between Panx1EGFP and Crmp2. (A) Representative confocal maximum intensity projections of vehicle- (left) and probenecid-treated (right) Panx1-EGFP-expressing N2a cells demonstrating PLA-positive Crmp2-Panx1 clusters (white). (B) Probenecid treatment significantly decreased mean fluorescence intensity of the PLA signal (vehicle: 26.0 ± 2.7 arb.u. per 100 μm 2 vs. probenecid: 17.1 ± 2.1 arb.u. per 100 μm 2 , p = 0.0037, n = 77 cells and n = 70 cells, respectively, Mann-Whitney test). (C) Controls for PLA included (i) cells were incubated with α-GFP anti-mouse and α-GFP anti-rabbit to serve as a positive control. (ii) No primary antibodies were included to serve as a negative control. Hoechst 33342 was used as a nuclear counterstain. Scale bars, 10 μm.
Techniques Used: Proximity Ligation Assay, Expressing, Fluorescence, MANN-WHITNEY, Incubation, Positive Control, Negative Control
Figure Legend Snippet: Probenecid treatment results in Crmp2 concentration at neurite tips. (Ai) Representative confocal images from N2a cells treated with vehicle (upper panels) or probenecid (lower panels) and immunostained for Crmp2. Crmp2 signal intensity is indicated in the heat maps. Hoechst 33342 was used as a nuclear counterstain. Scale bars: 20 μm. (ii) Crmp2 signal in probenecid-induced neurites was more abundant in neurite tips compared to the shaft, regardless of neurite length (10–30 μm, p < 0.0001, n = 38 neurites; 30–50 μm, p = 0.0003, n = 40 neurites; >50 μm, p < 0.0001, n = 48 neurites; Wilcoxon signed-rank test against a hypothetical median value of 1.0).
Techniques Used: Concentration Assay
Figure Legend Snippet: Working model: probenecid promotes neurite outgrowth by releasing Crmp2 thereby stabilizing microtubules. Panx1, which is developmentally regulated at a cellular and tissue level in neural precursor cells (NPCs), physically sequesters Crmp2, thereby inhibiting neuritogenesis until appropriate connections can be made. Probenecid binds to the first extracellular loop causing allosteric disruption of Crmp2 binding to the CT and resulting in a “release” of Crmp2 from the Panx1/Crmp2 complex. Free Crmp2 facilitates tubulin polymerization, and microtubule stabilization and bundling, thereby promoting neurite extension. MAP2 and Tau are microtubule-associated proteins that also contribute to microtubule stabilization in different types of neurites in the CNS and are included for context.
Techniques Used: Binding Assay